Precise genome-editing in human diseases: mechanisms, strategies and applications

被引:0
作者
Yanjiang Zheng
Yifei Li
Kaiyu Zhou
Tiange Li
Nathan J. VanDusen
Yimin Hua
机构
[1] West China Second University Hospital,Key Laboratory of Birth Defects and Related Diseases of Women and Children of MOE, Department of Pediatrics
[2] Sichuan University,Department of Cardiovascular Surgery, West China Hospital
[3] Sichuan University,Department of Pediatrics, Herman B Wells Center for Pediatric Research
[4] Indiana University School of Medicine,undefined
来源
Signal Transduction and Targeted Therapy | / 9卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Precise genome-editing platforms are versatile tools for generating specific, site-directed DNA insertions, deletions, and substitutions. The continuous enhancement of these tools has led to a revolution in the life sciences, which promises to deliver novel therapies for genetic disease. Precise genome-editing can be traced back to the 1950s with the discovery of DNA’s double-helix and, after 70 years of development, has evolved from crude in vitro applications to a wide range of sophisticated capabilities, including in vivo applications. Nonetheless, precise genome-editing faces constraints such as modest efficiency, delivery challenges, and off-target effects. In this review, we explore precise genome-editing, with a focus on introduction of the landmark events in its history, various platforms, delivery systems, and applications. First, we discuss the landmark events in the history of precise genome-editing. Second, we describe the current state of precise genome-editing strategies and explain how these techniques offer unprecedented precision and versatility for modifying the human genome. Third, we introduce the current delivery systems used to deploy precise genome-editing components through DNA, RNA, and RNPs. Finally, we summarize the current applications of precise genome-editing in labeling endogenous genes, screening genetic variants, molecular recording, generating disease models, and gene therapy, including ex vivo therapy and in vivo therapy, and discuss potential future advances.
引用
收藏
相关论文
共 784 条
[61]  
Dussoix D(2009)Breaking the code of DNA binding specificity of TAL-type III effectors Science 326 1509-426
[62]  
Arber W(2010)Xanthomonas AvrBs3 family-type III effectors: discovery and function Annu. Rev. Phytopathol. 48 419-883
[63]  
Arber W(2011)A TALE nuclease architecture for efficient genome editing Nat. Biotechnol. 29 143-260
[64]  
Dussoix D(2011)Efficient design and assembly of custom TALEN and other TAL effector-based constructs for DNA targeting Nucleic Acids Res. 39 e82-149
[65]  
Loenen WAM(2013)RNA-guided human genome engineering via Cas9 Science 339 823-1455
[66]  
Dryden DTF(2015)A mechanism for the suppression of homologous recombination in G1 cells Nature 528 422-789
[67]  
Raleigh EA(2013)A cell cycle-dependent regulatory circuit composed of 53BP1-RIF1 and BRCA1-CtIP controls DNA repair pathway choice Mol. Cell 49 872-5669.e25
[68]  
Wilson GG(2005)Cell cycle-dependent regulation of double-strand break repair: a role for the CDK Cell Cycle 4 258-204
[69]  
Murrayy NE(2016)In vivo genome editing via CRISPR/Cas9 mediated homology-independent targeted integration Nature 540 144-53
[70]  
Morrow JF(2020)ORANGE: a CRISPR/Cas9-based genome editing toolbox for epitope tagging of endogenous proteins in neurons PLoS Biol. 18 e3000665-225